Probiotics in Inflammatory Bowel Disease: Yet Another Mechanism of Action?

Gastroenterology

Volumn 131, Issue 6, 2006, Pages 2009-2012

  Fiocchi, Claudio ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL FACTOR; CD45 ANTIGEN; CORTICOSTEROID; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MESALAZINE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

DRUG CHOICE; DRUG MECHANISM; EDITORIAL; ENTERITIS; ESCHERICHIA COLI; HUMAN; INTESTINE FLORA; LACTOBACILLUS JOHNSONII; LACTOBACILLUS RHAMNOSUS; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; UNSPECIFIED SIDE EFFECT;

EID: 33845603197     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.10.051     Document Type: Editorial

References (25)

1. Fuller R. A review: probiotics in man and animals. J Appl Bacteriol 66 (1989) 365-378
2. Fiocchi C. Microbial factors in the pathogenesis of IBD. Bioscience Microflora 22 (2003) 5-14
3. Hooper L.V., and Gordon J.I. Commensal host-bacterial relationships in the gut. Science 292 (2001) 1115-1118
4. Macpherson A.J., and Harris N.L. Interactions between commensal bacteria and the immune system. Nat Rev Immunol 4 (2004) 478-485
5. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004) 1620-1633
6. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale?. Inflamm Bowel Dis 6 (2000) 107-115
7. Guarner F. The intestinal flora in inflammatory bowel disease: normal or abnormal?. Curr Opin Gastroenterol 21 (2005) 414-418
8. Marteau P., Lepage P., and Mangin I. Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl 4 (2004) 18-23
9. Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzocchi G., Poggioli G., and Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 305-309
10. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., Vitali B., Poggioli G., Miglioli M., and Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003) 1202-1209
11. Bibiloni R., Fedorak R.N., Tannock G.W., Madsen K.L., Gionchetti P., Campieri M., DeSimone C., and Sartor R.B. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100 (2005) 1539-1546
12. Rembachen B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., and Axon A.T.R. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354 (1999) 635-639
13. Guslandi M., Mezzi G., Sorghi M., and Testoni P.A. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45 (2000) 1462-1464
14. Prantera C., Scribano M.L., Falasco G., Andreoli A., and Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51 (2002) 405-409
15. Marteau P., Lemann M., Seksik P., Colombel J.-F., Bouhnik Y., Cardiot G., Soule J.C., Bourreille A., Metman E., Lerebours E., Carbonnel F., Dupas J.L., Veyrac M., Coffin B., Moreau J., Abitbol V., Blum-Sperisen S., and Mary J.Y. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55 (2006) 842-847
16. Bousvaros A., Guendalini S., Baldassano R.N., Botelho C., Evans J., Ferry G.D., Goldin B., Hartigan L., Kugathasan S., Levy J., Murray K.F., Oliva-Hemker M., Rosh J.R., Tolia V., Zholudev A., and Vanderhoof J.A. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 11 (2005) 833-839
17. Madsen K.L., Doyle J.S., Jewell L.D., Tavernini M.C., and Fedorak R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116 (1999) 1107-1114
18. Waidmann M., Bechtold O., Frick J.-S., Lehr H.-A., Schubert S., Dobrindt U., Loffler J., Bohn E., and Autenrieth I.B. Bacteroides vulgatus protects Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology 125 (2003) 162-177
19. Rachmilewitz D., Karmeli F., Takabayashi K., Hayashi T., Leider-Trejo L., Lee J., Leoni L.M., and Raz E. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122 (2002) 1428-1441
20. Dieleman L.A., Goerres M.S., Arends A., Sprengers D., Torrice C., Hoentjen F., Grenther W.B., and Sartor R.B. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52 (2003) 370-376
21. Penner R., Fedorak R.N., and Madsen K.L. Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. Curr Opin Pharmacol 5 (2005) 596-603
22. Mottett C., and Michetti P. Probiotics: wanted dead or alive. Dig Liver Dis 37 (2005) 3-6
23. Dalmasso G., Cottrez F., Imbert V., Lagadec P., Peyron J.-F., Rampal P., Czerucka D., and Groux H. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131 (2006) 1812-1825
24. Beaven S.W., and Abreu M.T. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 20 (2004) 318-327
25. Enache-Angoulvant A., and Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 41 (2005) 1559-1568